Transporters at CNS barrier sites: Obstacles or opportunities for drug delivery?

Current Pharmaceutical Design

Volumn 20, Issue 10, 2014, Pages 1422-1449

  Sanchez Covarrubias, Lucy ^a   Slosky, Lauren M ^a   Thompson, Brandon J ^a   Davis, Thomas P ^a   Ronaldson, Patrick T ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

ATP binding cassette transporters; Blood brain barrier; Blood cerebrospinal fluid barrier; Drug delivery; Neurovascular unit; Solute carriers; Transporters

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; MONOCARBOXYLATE TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PEPTIDE TRANSPORTER 1;

ACTIVE TRANSPORT; ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CELL JUNCTION; DIFFUSION; DRUG DELIVERY SYSTEM; ELECTROSTIMULATION; ENDOCYTOSIS; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; MEMBRANE TRANSPORT; MICROGLIA; NERVE CELL; NONHUMAN; OSMOSIS; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TIGHT JUNCTION; TRANSCYTOSIS;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS;

EID: 84897451667     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990463     Document Type: Review

References (382)

1. Ronladson PT, Davis TP. Targeted drug delivery to treat pain and cerebral hypoxia. Pharmacol Rev 2013; 65(1): 291-314.
2. Rolfe DF, Brown GC. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiological Rev 1997; 77(3): 731-58.
3. Oldendorf WH, Cornford ME, Brown WJ. The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol 1977; 1(5): 409-17.
4. Takakura Y, Audus KL, Borchardt RT. Blood-brain barrier: transport studies in isolated brain capillaries and in cultured brain endothelial cells. Adv Pharmacol (San Diego, Calif) 1991; 22: 137-65.
5. Fenstermacher J, Gross P, Sposito N, Acuff V, Pettersen S, Gruber K. Structural and functional variations in capillary systems within the brain. Ann New York Academy Sci 1988; 529: 21-30.
6. Betz AL, Firth JA, Goldstein GW. Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. Brain Res 1980; 192(1): 17-28.
7. Sanchez del Pino MM, Peterson DR, Hawkins RA. Neutral amino acid transport characterization of isolated luminal and abluminal membranes of the blood-brain barrier. J biological Chem 1995; 270(25): 14913-8.
8. Vorbrodt AW, Dobrogowska DH. Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist's view. Brain Res Brain Res Rev 2003; 42(3): 221-42.
9. Bendayan R, Lee G, Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microscopy Res Technique 2002; 57(5): 365-80.
10. Huber JD, Campos CR, Mark KS, Davis TP. Alterations in bloodbrain barrier ICAM-1 expression and brain microglial activation after lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol 2006; 290(2): H732-40.
11. Ronaldson PT, Demarco KM, Sanchez-Covarrubias L, Solinsky CM, Davis TP. Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J Cereb Blood Flow Metab 2009; 29(6): 1084-98.
12. Ronaldson PT, Finch JD, DeMarco KM, Quigley CE, Davis TP. Inflammatory Pain Signals an Increase in Functional Expression of Organic Anion Transporting Polypeptide 1a4 at the Blood-Brain Barrier. J Pharmacol Exp Ther 2011; 336(3): 827-39.
13. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid regulation of Pglycoprotein at the blood-brain barrier by endothelin-1. Mol Pharmacol 2004; 66(3): 387-94.
14. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57(2): 173-85.
15. Abbruscato TJ, Davis TP. Combination of hypoxia/aglycemia compromises in vitro blood-brain barrier integrity. J Pharmacol Exp Ther 1999; 289(2): 668-75.
16. Iyer S, Ferreri DM, DeCocco NC, Minnear FL, Vincent PA. VEcadherin-p120 interaction is required for maintenance of endothelial barrier function. Am J Physiol Lung Cellular Mol Physiol 2004; 286(6): L1143-53.
17. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57(2): 178-201.
18. Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 1990; 429: 47-62.
19. Ronaldson PT, Davis TP. Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr Pharm Des 2012; 18(25): 3624-44.
20. Dejana E, Lampugnani MG, Martinez-Estrada O, Bazzoni G. The molecular organization of endothelial junctions and their functional role in vascular morphogenesis and permeability. Int J Developmental Biol 2000; 44(6): 743-8.
21. Yeung D, Manias JL, Stewart DJ, Nag S. Decreased junctional adhesion molecule-A expression during blood-brain barrier breakdown. Acta Neuropathologica 2008; 115(6): 635-42.
22. Hoffman WH, Stamatovic SM, Andjelkovic AV. Inflammatory mediators and blood brain barrier disruption in fatal brain edema of diabetic ketoacidosis. Brain Res 2009; 1254: 138-48.
23. Haarmann A, Deiss A, Prochaska J, et al. Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown. PloS one 2010; 5(10): e13568.
24. Del Maschio A, De Luigi A, Martin-Padura I, et al. Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). J Experimental Med 1999; 190(9): 1351-6.
25. Furuse M, Hirase T, Itoh M, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J cell Biol 1993; 123(6 Pt 2): 1777-88.
26. Lippoldt A, Kniesel U, Liebner S, et al. Structural alterations of tight junctions are associated with loss of polarity in stroke-prone spontaneously hypertensive rat blood-brain barrier endothelial cells. Brain Res 2000; 885(2): 251-61.
27. McCarthy KM, Skare IB, Stankewich MC, et al. Occludin is a functional component of the tight junction. J Cell Sci 1996; 109: 2287-98.
28. Balda MS, Whitney JA, Flores C, Gonzalez S, Cereijido M, Matter K. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apicalbasolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J cell Biol 1996; 134(4): 1031-49.
29. McCaffrey G, Staatz WD, Quigley CA, Nametz N, Seelbach MJ, Campos CR, et al. Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo. J Neurochem 2007; 103(6): 2540-55.
30. McCaffrey G, Seelbach MJ, Staatz WD, et al. Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. J Neurochem 2008; 106(6): 2395-409.
31. Lochhead JJ, McCaffrey G, Quigley CE, et al. Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J Cereb Blood Flow Metab 2010; 30(9): 1625-36.
32. Lochhead JJ, McCaffrey G, Sanchez-Covarrubias L, et al. Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain. Am J Physiol Heart Circ Physiol 2012; 302(3): H582-93.
33. Bauer H-CT, A; Bauer, H. Proteins of the tight junction in the blood brain barrier. In: Sharma HSW, J., editor. Blood-Spinal Chord and Brain Barriers in Health and Disease. San Diego: Elsevier; 2004.
34. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and-2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J cell Biol 1998; 141(7): 1539-50.
35. Furuse M, Sasaki H, Tsukita S. Manner of interaction of heterogeneous claudin species within and between tight junction strands. J cell Biol 1999; 147(4): 891-903.
36. Kubota K, Furuse M, Sasaki H, et al. Ca(2+)-independent celladhesion activity of claudins, a family of integral membrane proteins localized at tight junctions. Current biology: CB 1999; 9(18): 1035-8.
37. Gonzalez-Mariscal L, Betanzos A, Avila-Flores A. MAGUK proteins: structure and role in the tight junction. Seminars Cell Developmental Biol 2000; 11(4): 315-24.
38. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J cell Biol 1986; 103(3): 755-66.
39. Howarth AG, Hughes MR, Stevenson BR. Detection of the tight junction-associated protein ZO-1 in astrocytes and other nonepithelial cell types. Am J physiology 1992; 262(2 Pt 1): C461-9.
40. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biological Chem 1998; 273(45): 29745-53.
41. Abbruscato TJ, Lopez SP, Mark KS, Hawkins BT, Davis TP. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J Pharm Sci 2002; 91(12): 2525-38.
42. Mark KS, Davis TP. Cerebral microvascular changes in permeability and tight junctions induced by hypoxiareoxygenation. Am J Physiol Heart Circ Physiol 2002; 282(4): H1485-94.
43. Umeda K, Matsui T, Nakayama M, et al. Establishment and characterization of cultured epithelial cells lacking expression of ZO-1. J Biological Chem 2004; 279(43): 44785-94.
44. Inoko A, Itoh M, Tamura A, Matsuda M, Furuse M, Tsukita S. Expression and distribution of ZO-3, a tight junction MAGUK protein, in mouse tissues. Genes to cells: Devoted Mol Cellular Mechanisms 2003; 8(11): 837-45.
45. Raff MC, Abney ER, Cohen J, Lindsay R, Noble M. Two types of astrocytes in cultures of developing rat white matter: differences in morphology, surface gangliosides, and growth characteristics. J neuroscience: the official J Soc Neurosci 1983; 3(6): 1289-300. E.
46. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7(1): 41-53.
47. Kacem K, Lacombe P, Seylaz J, Bonvento G. Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: a confocal microscopy study. Glia 1998; 23(1): 1-10.
48. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987; 325(6101): 253-7.
49. Willis CL, Leach L, Clarke GJ, Nolan CC, Ray DE. Reversible disruption of tight junction complexes in the rat blood-brain barrier, following transitory focal astrocyte loss. Glia 2004; 48(1): 1-13.
50. Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int 2006; 48(5): 394-403.
51. Pardridge WM, Golden PL, Kang YS, Bickel U. Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem 1997; 68(3): 1278-85.
52. van Vliet EA, Redeker S, Aronica E, Edelbroek PM, Gorter JA. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia 2005; 46(10): 1569-80.
53. Aronica E, Gorter JA, Redeker S, et al. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 2005; 46(6): 849-57.
54. Ronaldson PT, Persidsky Y, Bendayan R. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. Glia 2008; 56(16): 1711-35.
55. Kofler J, Wiley CA. Microglia: key innate immune cells of the brain. Toxicologic pathology 2011; 39(1): 103-14.
56. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiological Rev 2011; 91(2): 461-553.
57. Berezowski V, Landry C, Dehouck MP, Cecchelli R, Fenart L. Contribution of glial cells and pericytes to the mRNA profiles of Pglycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. Brain Res 2004; 1018(1): 1-9.
58. Gibson CJ, Hossain M, Richardson JR, Aleksunes LM. Inflammatory Regulation of ABC Efflux Transporter Expression and Function in Microglia. J Pharmacol Exp Ther 2012.
59. Sa-Pereira I, Brites D, Brito MA. Neurovascular unit: a focus on pericytes. Mol Neurobiol 2012; 45(2): 327-47.
60. Dore-Duffy P, Cleary K. Morphology and properties of pericytes. Methods Mol Biol 2011; 686: 49-68.
61. Hori S, Ohtsuki S, Hosoya K, Nakashima E, Terasaki T. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J Neurochem 2004; 89(2): 503-13.
62. Al Ahmad A, Taboada CB, Gassmann M, Ogunshola OO. Astrocytes and pericytes differentially modulate blood-brain barrier characteristics during development and hypoxic insult. J Cereb Blood Flow Metab 2011; 31(2): 693-705.
63. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010; 468(7323): 562-6.
64. Bendayan R, Ronaldson PT, Gingras D, Bendayan M. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J histochemistry and cytochemistry: official J Histochem Soc 2006; 54(10): 1159-67.
65. Saint-Pol J, Vandenhaute E, Boucau MC, Candela P, Dehouck L, Cecchelli R, et al. Brain pericytes ABCA1 expression mediates cholesterol efflux but not cellular amyloid-beta peptide accumulation. J Alzheimer's disease: JAD 2012; 30(3): 489-503.
66. Ben-Menachem E, Johansson BB, Svensson TH. Increased vulnerability of the blood-brain barrier to acute hypertension following depletion of brain noradrenaline. J Neural Transmission 1982; 53(2-3): 159-67.
67. Cohen Z, Molinatti G, Hamel E. Astroglial and vascular interactions of noradrenaline terminals in the rat cerebral cortex. J Cereb Blood Flow Metab 1997; 17(8): 894-904.
68. Cohen Z, Bonvento G, Lacombe P, Hamel E. Serotonin in the regulation of brain microcirculation. Progress in neurobiology 1996; 50(4): 335-62.
69. Tong XK, Hamel E. Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience 1999; 92(1): 163-75.
70. Vaucher E, Hamel E. Cholinergic basal forebrain neurons project to cortical microvessels in the rat: electron microscopic study with anterogradely transported Phaseolus vulgaris leucoagglutinin and choline acetyltransferase immunocytochemistry. J neuroscience: the official J Society Neurosci 1995; 15(11): 7427-41.
71. Vaucher E, Tong XK, Cholet N, Lantin S, Hamel E. GABA neurons provide a rich input to microvessels but not nitric oxide neurons in the rat cerebral cortex: a means for direct regulation of local cerebral blood flow. J Comparative Neurol 2000; 421(2): 161-71.
72. Yarnitsky D, Gross Y, Lorian A, et al. Blood-brain barrier opened by stimulation of the parasympathetic sphenopalatine ganglion: a new method for macromolecule delivery to the brain. J Neurosurgery 2004; 101(2): 303-9.
73. Lopez NE, Krzyzaniak MJ, Costantini TW, et al. Vagal nerve stimulation decreases blood-brain barrier disruption after traumatic brain injury. J Trauma Acute Care Surgery 2012; 72(6): 1562-6.
74. Rosenstein JM, Krum JM, Ruhrberg C. VEGF in the nervous system. Organogenesis 2010; 6(2): 107-14.
75. Davis B, Tang J, Zhang L, Mu D, Jiang X, Biran V, et al. Role of vasodilator stimulated phosphoprotein in VEGF induced bloodbrain barrier permeability in endothelial cell monolayers. International J developmental neuroscience: the official J the International Society for Developmental Neurosci 2010; 28(6): 423-8.
76. Engelhardt B, Sorokin L. The blood-brain and the bloodcerebrospinal fluid barriers: function and dysfunction. Seminars Immunopathol 2009; 31(4): 497-511.
77. Strazielle N, Ghersi-Egea JF. Choroid plexus in the central nervous system: biology and physiopathology. J Neuropathol Experimental Neurol 2000; 59(7): 561-74.
78. Johanson CE, Stopa EG, McMillan PN. The blood-cerebrospinal fluid barrier: structure and functional significance. Methods Mol Biol 2011; 686: 101-31.
79. Davson H, Hollingsworth G, Segal MB. The mechanism of drainage of the cerebrospinal fluid. Brain: J Neurol 1970; 93(4): 665-78.
80. Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, I. Adult brain. Clin Exp Pharmacol Physiol 1999; 26(1): 11-9.
81. Felgenhauer K. Protein size and cerebrospinal fluid composition. Klinische Wochenschrift 1974; 52(24): 1158-64.
82. Azzi G, Bernaudin JF, Bouchaud C, Bellon B, Fleury-Feith J. Permeability of the normal rat brain, spinal cord and dorsal root ganglia microcirculations to immunoglobulins G. Biol Cell/under Auspices Eur Cell Biol Organization 1990; 68(1): 31-6.
83. Tachikawa M, Ozeki G, Higuchi T, Akanuma SI, Tsuji K, Hosoya KI. Role of the blood-cerebrospinal fluid barrier transporter as a cerebral clearance system for prostaglandin E(2) produced in the brain. J Neurochem 2012.
84. Choudhuri S, Cherrington NJ, Li N, Klaassen CD. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug metabolism and disposition: the Biological Fate Chemicals 2003; 31(11): 1337-45.
85. Smith DE, Johanson CE, Keep RF. Peptide and peptide analog transport systems at the blood-CSF barrier. Adv Drug Delivery Rev 2004; 56(12): 1765-91.
86. Roberts LM, Black DS, Raman C, et al. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebralspinal fluid barrier by in vivo biotinylation. Neuroscience 2008; 155(2): 423-38.
87. Philp NJ, Yoon H, Lombardi L. Mouse MCT3 gene is expressed preferentially in retinal pigment and choroid plexus epithelia. Am J Physiol Cell Physiol 2001; 280(5): C1319-26.
88. Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinalfluid drug-permeability barrier. Proc Natl Acad Sci USA 1999; 96(7): 3900-5.
89. Halwachs S, Lakoma C, Schafer I, Seibel P, Honscha W. The antiepileptic drugs phenobarbital and carbamazepine reduce transport of methotrexate in rat choroid plexus by down-regulation of the reduced folate carrier. Mol Pharmacol 2011; 80(4): 621-9.
90. Xia LZ, M.; Wang, J. Nucleoside Transporters: CNTs and ENTs. In: You GMME, editor. Drug Transportes: molecular characterization and role in drug disposition. Hoboken, NJ: John Wiley & Sons, Inc; 2007. p. 171-200.
91. Habgood MD, Begley DJ, Abbott NJ. Determinants of passive drug entry into the central nervous system. Cellular Mol Neurobiol 2000; 20(2): 231-53.
92. Wolka AM, Huber JD, Davis TP. Pain and the blood-brain barrier: obstacles to drug delivery. Adv Drug Delivery Rev 2003; 55(8): 987-1006.
93. Walsh CTS-B, R. Levine's Pharmacology: Drug interactions and reactions. Seventh ed. United Kingdon: Taylor Francis 2005 2005. 545 p.
94. De Gregori S, De Gregori M, Ranzani GN, Allegri M, Minella C, Regazzi M. Morphine metabolism, transport and brain disposition. Metabolic Brain Disease 2012; 27(1): 1-5.
95. Au-Yeung SC, Rurak DW, Gruber N, Riggs KW. A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. Drug metabolism and disposition: the biological fate of chemicals 2006; 34(6): 955-60.
96. Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol transporters. Pflügers Archiv Eur J Physiol 2004; 447(5): 480-9.
97. del Amo EM, Urtti A, Yliperttula M. Pharmacokinetic role of Ltype amino acid transporters LAT1 and LAT2. European J Pharm Sciences: official J Eur Federation Pharm Sci 2008; 35(3): 161-74.
98. Simionescu M, Gafencu A, Antohe F. Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey. Microscopy research and technique 2002; 57(5): 269-88.
99. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012.
100. Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE. Receptor-mediated transcytosis of transferrin across the bloodbrain barrier. J Neurosci Res 1987; 18(2): 299-304.
101. King GL, Johnson SM. Receptor-mediated transport of insulin across endothelial cells. Science (New York, NY) 1985; 227(4694): 1583-6.
102. Scherrmann JM. Drug delivery to brain via the blood-brain barrier. Vascular Pharmacol 2002; 38(6): 349-54.
103. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000; 89(11): 1371-88.
104. Boron WF, Boulep, E. L. Medical Physiology. Philedelphia, PA: Elsevier Saunders; 2005. 1269 p.
105. Abbott NJ, Romero IA. Transporting therapeutics across the bloodbrain barrier. Mol Med Today 1996; 2(3): 106-13.
106. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11(7): 1156-66.
107. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Ann Rev Genetics 1995; 29: 607-49.
108. Hyde SC, Emsley P, Hartshorn MJ, et al. Structural model of ATPbinding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990; 346(6282): 362-5.
109. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems 2008; 38(7-8): 802-32.
110. Hennessy M, Spiers JP. A primer on the mechanics of Pglycoprotein the multidrug transporter. Pharmacological research: the official J Italian Pharmacological Soc 2007; 55(1): 1-15.
111. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Applied Pharmacol 2005; 204(3): 216-37.
112. You GMME. Overview of Drug Transporter Families. In: You GMME, editor. Drug Transporters: molecular characterization and role in drug disposition. Hoboken, NJ: John Wiley & Sons, Inc.; 2007. p. 1-10.
113. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J lipid Res 2001; 42(7): 1007-17.
114. Santamarina-Fojo S, Remaley AT, Neufeld EB, Brewer HB, Jr. Regulation and intracellular trafficking of the ABCA1 transporter. J lipid Res 2001; 42(9): 1339-45.
115. Puntoni M, Sbrana F, Bigazzi F, Sampietro T. Tangier disease: epidemiology, pathophysiology, and management. American J cardiovascular drugs: drugs, devices, and other Interventions 2012; 12(5): 303-11.
116. Glaser B, Blech I, Krakinovsky Y, et al. ABCC8 mutation allele frequency in the Ashkenazi Jewish population and risk of focal hyperinsulinemic hypoglycemia. Genetics in medicine: official J Am College Med Genetics 2011; 13(10): 891-4.
117. Fournet JC, Mayaud C, de Lonlay P, et al. Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in ABCC8 or KCNJ11. Am J Pathol 2001; 158(6): 2177-84.
118. Wada M, Toh S, Taniguchi K, et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Human Molecular genetics 1998; 7(2): 203-7.
119. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nature Medicine 2012; 18(4): 509-19.
120. Wanders RJ, Visser WF, van Roermund CW, Kemp S, Waterham HR. The peroxisomal ABC transporter family. Pflugers Archiv: Eur J Physiol 2007; 453(5): 719-34.
121. Cappa M, Bizzarri C, Vollono C, Petroni A, Banni S. Adrenoleukodystrophy. Endocrine Development 2011; 20: 149-60.
122. Tian Y, Han X, Tian DL. The biological regulation of ABCE1. IUBMB life 2012; 64(10): 795-800.
123. Ronaldson PTBKB, R. Drug Transport in the Brain. In: You GMME, editor. Drug Transporters: molecular characterization and role in drug disposition. Hoboken, N. J.: John Wiley & Sons, Inc.; 2007. p. 411-62.
124. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (Pglycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47(3): 381-9.
125. Roninson IB, Chin JE, Choi KG, et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 1986; 83(12): 4538-42.
126. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84(9): 3004-8.
127. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75(3): 451-62.
128. Gribar JJ, Ramachandra M, Hrycyna CA, Dey S, Ambudkar SV. Functional characterization of glycosylation-deficient human Pglycoprotein using a vaccinia virus expression system. J Membrane Biol 2000; 173(3): 203-14.
129. Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR. Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol 2010; 78(2): 310-8.
130. Ling V, Thompson LH. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cellular Physiol 1974; 83(1): 103-16.
131. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta 1976; 455(1): 152-62.
132. Sharom FJ. Multidrug Resistance Protein: P-glycoprotein. In: Morris GYaME, editor. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Hoboken, NJ: John Wiley & Sons, Inc.; 2007. p. 263-318.
133. Schinkel AH, Smit JJM, Vantellingen O, et al. Disruption of the Mouse Mdr1a P-Glycoprotein Gene Leads to a Deficiency in the Blood-Brain-Barrier and to Increased Sensitivity to Drugs. Cell 1994; 77(4): 491-502.
134. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug metabolism and disposition: Biological Fate Chemicals 2005; 33(1): 165-74.
135. Golden PL, Pardridge WM. P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res 1999; 819(1-2): 143-6.
136. Schlachetzki F, Pardridge WM. P-glycoprotein and caveolin-1 alpha in endothelium and astrocytes of primate brain. Neuroreport 2003; 14(16): 2041-6.
137. Ronaldson PT, Bendayan M, Gingras D, Piquette-Miller M, Bendayan R. Cellular localization and functional expression of Pglycoprotein in rat astrocyte cultures. J Neurochem 2004; 89(3): 788-800.
138. Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev 2001; 53(4): 569-96.
139. Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, Loscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004; 123(3): 751-9.
140. Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Medical science monitor: Int Med J Exp Clin Res 2004; 10(1): RA5-14.
141. Demeule M, Regina A, Jodoin J, et al. Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vasc Pharmacol 2002; 38(6): 339-48.
142. Shirasaka Y, Suzuki K, Shichiri M, Nakanishi T, Tamai I. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and Pglycoprotein/multidrug resistance 1. Drug Metabol Pharmacokinetics 2011; 26(2): 171-9.
143. Shirasaka Y, Suzuki K, Nakanishi T, Tamai I. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J Pharm Sci 2011; 100(9): 3843-53.
144. Seelbach MJ, Brooks TA, Egleton RD, Davis TP. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J Neurochem 2007; 102(5): 1677-90.
145. Chen C, Pollack GM. Altered disposition and antinociception of [D-penicillamine(2, 5)] enkephalin in mdr1a-gene-deficient mice. J Pharmacol Exp Ther 1998; 287(2): 545-52.
146. Chen C, Pollack GM. Extensive biliary excretion of the model opioid peptide [D-PEN2, 5] enkephalin in rats. Pharm Res 1997; 14(3): 345-50.
147. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer control: J Moffitt Cancer Center 2003; 10(2): 159-65.
148. Goard CA, Mather RG, Vinepal B, et al. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer J Int Cancer 2010; 127(12): 2936-48.
149. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biological Chem 1990; 265(17): 10073-80.
150. Lee JS, Scala S, Matsumoto Y, et al. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cellular Biochem 1997; 65(4): 513-26.
151. Nakagawa M, Schneider E, Dixon KH, et al. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 1992; 52(22): 6175-81.
152. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95(26): 15665-70.
153. Diop NK, Hrycyna CA. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry 2005; 44(14): 5420-9.
154. Mohrmann K, van Eijndhoven MA, Schinkel AH, Schellens JH. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemotherap Pharmacol 2005; 56(4): 344-50.
155. Graf GA, Li WP, Gerard RD, et al. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J clinical Investigation 2002; 110(5): 659-69.
156. Graf GA, Yu L, Li WP, et al. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biological Chem 2003; 278(48): 48275-82.
157. Fetsch PA, Abati A, Litman T, et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer letters 2006; 235(1): 84-92.
158. Eisenblatter T, Huwel S, Galla HJ. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 2003; 971(2): 221-31.
159. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB journal: official publication Federation Am Soc Exp Biol 2003; 17(14): 2085-7.
160. Lee G, Babakhanian K, Ramaswamy M, Prat A, Wosik K, Bendayan R. Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. Pharm Res 2007; 24(7): 1262-74.
161. Fujiyoshi M, Ohtsuki S, Hori S, Tachikawa M, Terasaki T. 24Shydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical-and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. J Neurochem 2007; 100(4): 968-78.
162. Hori S, Ohtsuki S, Tachikawa M, et al. Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem 2004; 90(3): 526-36.
163. Cooray HC, Janvilisri T, van Veen HW, Hladky SB, Barrand MA. Interaction of the breast cancer resistance protein with plant polyphenols. Biochemical Biophys Res Communications 2004; 317(1): 269-75.
164. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004; 65(5): 1208-16.
165. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 2005; 312(1): 44-52.
166. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005; 65(7): 2577-82.
167. Staud F, Pavek P. Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 2005; 37(4): 720-5.
168. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS Journal 2005; 7(1): E118-33.
169. Kellner U, Hutchinson L, Seidel A, et al. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int J Cancer J Int Cancer 1997; 71(5): 817-24.
170. Rabindran SK, He H, Singh M, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 1998; 58(24): 5850-8.
171. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999; 59(17): 4237-41.
172. Zhang Y, Han H, Elmquist WF, Miller DW. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 2000; 876(1-2): 148-53.
173. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92(16): 1295-302.
174. Lee YJ, Kusuhara H, Sugiyama Y. Do multidrug resistanceassociated protein-1 and-2 play any role in the elimination of estradiol-17 beta-glucuronide and 2, 4-dinitrophenyl-S-glutathione across the blood-cerebrospinal fluid barrier? J Pharm Sci 2004; 93(1): 99-107.
175. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev 2006; 58(2): 140-61.
176. Hirrlinger J, Konig J, Dringen R. Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J Neurochem 2002; 82(3): 716-9.
177. Ballerini P, Di Iorio P, Ciccarelli R, et al. Glial cells express multiple ATP binding cassette proteins which are involved in ATP release. Neuroreport 2002; 13(14): 1789-92.
178. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001; 167(1): 3-23.
179. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003; 22(47): 7537-52.
180. Leslie EM, Deeley RG, Cole SP. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug metabolism and disposition: Biological Fate Chemicals 2003; 31(1): 11-5.
181. Nies ATR M, Keppler D. Mutlidrug Resistance Proteins of the ABCC Subfamily. In: You GMME, editor. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Hoboken, NJ: John Wiley & Sons, Inc.; 2007. p. 263-318.
182. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG. The blood-brain barrier and oncology: new insights into function and modulation. Cancer treatment Rev 2000; 26(6): 449-62.
183. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biological Chem 2001; 276(49): 46400-7.
184. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology (Baltimore, Md) 2003; 38(2): 374-84.
185. Nies AT, Jedlitschky G, Konig J, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004; 129(2): 349-60.
186. Wijnholds J, Mol CA, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000; 97(13): 7476-81.
187. Kusuhara H, Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx: J Am Society Experimental NeuroTherapeut 2005; 2(1): 73-85.
188. Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metabol 2004; 5(1): 63-84.
189. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Archiv: Eur J Physiol 2004; 447(5): 465-8.
190. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Archiv: Eur J Physiol 2004; 447(5): 653-65.
191. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. JBr J Pharmacol 2012; 165(5): 1260-87.
192. Westholm DE, Rumbley JN, Salo DR, Rich TP, Anderson GW. Organic anion-transporting polypeptides at the blood-brain and blood-cerebrospinal fluid barriers. Current Topics Developmental Biol 2008; 80: 135-70.
193. Sai Y, Kaneko Y, Ito S, et al. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug metabolism and disposition: Biological Fate Chemicals 2006; 34(8): 1423-31.
194. Varma MV, Rotter CJ, Chupka J, et al. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm 2011; 8(4): 1303-13.
195. Nozawa T, Sugiura S, Nakajima M, et al. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: Implications for understanding troglitazone hepatotoxicity. Drug Metabol Disposition 2004; 32(3): 291-4.
196. Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 2009; 296(3): C570-82.
197. Martinez-Becerra P, Briz O, Romero MR, et al. Further Characterization of the Electrogenicity and pH Sensitivity of the Human Organic Anion-Transporting Polypeptides OATP1B1 and OATP1B3. Mol Pharmacol 2011; 79(3): 596-607.
198. Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N. Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol-Gastr L 2007; 293(1): G271-G8.
199. Lee W, Glaeser H, Smith LH, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biological Chem 2005; 280(10): 9610-7.
200. Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011; 117(2): 333-45.
201. Hau VS, Huber JD, Campos CR, Davis RT, Davis TP. Effect of lambda-carrageenan-induced inflammatory pain on brain uptake of codeine and antinociception. Brain Res 2004; 1018(2): 257-64.
202. McCaffrey G, Staatz WD, Sanchez-Covarrubias L, et al. Pglycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia. J Neurochem 2012; 122(5): 962-75.
203. Huber RD, Gao B, Sidler Pfandler MA, et al. Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol Cell Physiol 2007; 292(2): C795-806.
204. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol (Baltimore, Md) 2002; 16(10): 2283-96.
205. Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic aniontransporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120(2): 525-33.
206. Bronger H, Konig J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 2005; 65(24): 11419-28.
207. Ohtsuki S, Takizawa T, Takanaga H, et al. In vitro study of the functional expression of organic anion transporting polypeptide 3 at rat choroid plexus epithelial cells and its involvement in the cerebrospinal fluid-to-blood transport of estrone-3-sulfate. Mol Pharmacol 2003; 63(3): 532-7.
208. Ronaldson PT, Davis TP. Targeted drug delivery to treat pain and cerebral hypoxia. Pharmacol Rev 2013; 65(1): 291-314.
209. Angeletti RH, Novikoff PM, Juvvadi SR, Fritschy JM, Meier PJ, Wolkoff AW. The choroid plexus epithelium is the site of the organic anion transport protein in the brain. Proc Natl Acad Sci USA 1997; 94(1): 283-6.
210. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochimica et biophysica acta 2003; 1609(1): 1-18.
211. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 2000; 294(1): 73-9.
212. Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, Sugiyama Y. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharmaceutical Res 1999; 16(6): 904-8.
213. Sugiyama D, Kusuhara H, Taniguchi H, et al. Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine. J Biological Chem 2003; 278(44): 43489-95.
214. Mikkaichi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 2004; 101(10): 3569-74.
215. Kis B, Isse T, Snipes JA, et al. Effects of LPS stimulation on the expression of prostaglandin carriers in the cells of the blood-brain and blood-cerebrospinal fluid barriers. J Appl Physiol 2006; 100(4): 1392-9.
216. Simonson GD, Vincent AC, Roberg KJ, Huang Y, Iwanij V. Molecular cloning and characterization of a novel liver-specific transport protein. J Cell Sci 1994; 107 (Pt 4): 1065-72.
217. Mori K, Ogawa Y, Ebihara K, et al. Kidney-specific expression of a novel mouse organic cation transporter-like protein. FEBS letters 1997; 417(3): 371-4.
218. Brady KP, Dushkin H, Fornzler D, et al. A novel putative transporter maps to the osteosclerosis (oc) mutation and is not expressed in the oc mutant mouse. Genomics 1999; 56(3): 254-61.
219. Kusuhara H, Sekine T, Utsunomiya-Tate N, et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J biological Chem 1999; 274(19): 13675-80.
220. Cha SH, Sekine T, Kusuhara H, et al. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biological Chem 2000; 275(6): 4507-12.
221. Lopez-Nieto CE, You G, Bush KT, Barros EJ, Beier DR, Nigam SK. Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney. J Biological Chem 1997; 272(10): 6471-8.
222. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biological Chem 1997; 272(30): 18526-9.
223. Sweet DH, Pritchard JB. The molecular biology of renal organic anion and organic cation transporters. Cell Biochem Biophys 1999; 31(1): 89-118.
224. Eraly SA, Nigam SK. Novel human cDNAs homologous to Drosophila Orct and mammalian carnitine transporters. Biochemical Biophys Res communicat 2002; 297(5): 1159-66.
225. Monte JC, Nagle MA, Eraly SA, Nigam SK. Identification of a novel murine organic anion transporter family member, OAT6, expressed in olfactory mucosa. Biochemical Biophys Res communicat 2004; 323(2): 429-36.
226. Sekine T, Cha SH, Endou H. The multispecific organic anion transporter (OAT) family. Pflugers Archiv: Eur J Physiol 2000; 440(3): 337-50.
227. Emami Riedmaier A, Nies AT, Schaeffeler E, Schwab M. Organic anion transporters and their implications in pharmacotherapy. Pharmacol Rev 2012; 64(3): 421-49.
228. Youngblood GL, Sweet DH. Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney. Am J Physiol Renal Physiol 2004; 287(2): F236-44.
229. Burckhardt BC, Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol, Biochem Pharmacol 2003; 146: 95-158.
230. Sekine T, Cha SH, Tsuda M, et al. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS letters 1998; 429(2): 179-82.
231. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8) knockout mice. J Biological Chem 2002; 277(30): 26934-43.
232. Nagata Y, Kusuhara H, Endou H, Sugiyama Y. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol 2002; 61(5): 982-8.
233. Kikuchi R, Kusuhara H, Sugiyama D, Sugiyama Y. Contribution of organic anion transporter 3 (Slc22a8) to the elimination of paminohippuric acid and benzylpenicillin across the blood-brain barrier. J Pharmacol Exp Ther 2003; 306(1): 51-8.
234. Xu G, Bhatnagar V, Wen G, Hamilton BA, Eraly SA, Nigam SK. Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney international 2005; 68(4): 1491-9.
235. Kusch-Poddar M, Drewe J, Fux I, Gutmann H. Evaluation of the immortalized human brain capillary endothelial cell line BB19 as a human cell culture model for the blood-brain barrier. Brain Res 2005; 1064(1-2): 21-31.
236. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H. Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther 2002; 301(1): 293-8.
237. Babu E, Takeda M, Narikawa S, et al. Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochimica et Biophysica Acta 2002; 1590(1-3): 64-75.
238. Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 2004; 308(1): 2-9.
239. Zhang L, Gorset W, Dresser MJ, Giacomini KM. The interaction of n-tetraalkylammonium compounds with a human organic cation transporter, hOCT1. J Pharmacol Exp Ther 1999; 288(3): 1192-8.
240. Koepsell H, Gorboulev V, Arndt P. Mol Pharmacol of organic cation transporters in kidney. J Membrane Biol 1999; 167(2): 103-17.
241. Koepsell H. Organic cation transporters in intestine, kidney, liver, and brain. Ann Rev Phys 1998; 60: 243-66.
242. Dresser MJ, Leabman MK, Giacomini KM. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 2001; 90(4): 397-421.
243. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994; 372(6506): 549-52.
244. Grundemann D, Babin-Ebell J, Martel F, Ording N, Schmidt A, Schomig E. Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells. J Biological Chem 1997; 272(16): 10408-13.
245. Gorboulev V, Ulzheimer JC, Akhoundova A, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA and cell biology 1997; 16(7): 871-81.
246. Ullrich KJ. Specificity of transporters for 'organic anions' and 'organic cations' in the kidney. Biochimica et Biophysica Acta 1994; 1197(1): 45-62.
247. Ciarimboli G, Schlatter E. Regulation of organic cation transport. Pflugers Archiv: Eur J Physiol 2005; 449(5): 423-41.
248. Pao SS, Paulsen IT, Saier MH, Jr. Major facilitator superfamily. Microbiology and molecular biology reviews: MMBR 1998; 62(1): 1-34.
249. Dickens D, Owen A, Alfirevic A, et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochemical Pharmacol 2012; 83(6): 805-14.
250. Slitt AL, Cherrington NJ, Hartley DP, Leazer TM, Klaassen CD. Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. Drug metabolism and disposition: the biological fate of chemicals 2002; 30(2): 212-9.
251. Grundemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1998; 1(5): 349-51.
252. Busch AE, Karbach U, Miska D, et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 1998; 54(2): 342-52.
253. Wu X, Huang W, Ganapathy ME, et al. Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol 2000; 279(3): F449-58.
254. Kekuda R, Prasad PD, Wu X, et al. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biological Chem 1998; 273(26): 15971-9.
255. Grundemann D, Koster S, Kiefer N, et al. Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biological Chem 1998; 273(47): 30915-20.
256. Wu X, Kekuda R, Huang W, et al. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biological Chem 1998; 273(49): 32776-86.
257. Schmitt A, Mossner R, Gossmann A, et al. Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. J Neurosci Res 2003; 71(5): 701-9.
258. Kristufek D, Rudorfer W, Pifl C, Huck S. Organic cation transporter mRNA and function in the rat superior cervical ganglion. J Physiol 2002; 543(Pt 1): 117-34.
259. Okura T, Hattori A, Takano Y, et al. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug metabolism and disposition: the Biological Fate Chemicals 2008; 36(10): 2005-13.
260. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Archiv: Eur J Physiol 2004; 447(5): 666-76.
261. Wawrzenczyk A, Nalecz KA, Nalecz MJ. Effect of externally added carnitine on the synthesis of acetylcholine in rat cerebral cortex cells. Neurochem Int 1995; 26(6): 635-41.
262. Tamai I, Ohashi R, Nezu JI, et al. Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biological Chem 2000; 275(51): 40064-72.
263. Koepsell H, Schmitt BM, Gorboulev V. Organic cation transporters. Rev Physiol, Biochem Pharmacol 2003; 150: 36-90.
264. Tamai I, Yabuuchi H, Nezu J, et al. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS letters 1997; 419(1): 107-11.
265. Wu X, George RL, Huang W, et al. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochimica Biophysica Acta 2000; 1466(1-2): 315-27.
266. Yabuuchi H, Tamai I, Nezu J, et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther 1999; 289(2): 768-73.
267. Tamai I, Ohashi R, Nezu J, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biological Chem 1998; 273(32): 20378-82.
268. Wu X, Huang W, Prasad PD, et al. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 1999; 290(3): 1482-92.
269. Kido Y, Tamai I, Ohnari A, et al. Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 2001; 79(5): 959-69.
270. Inano A, Sai Y, Nikaido H, et al. Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm Drug Disposition 2003; 24(8): 357-65.
271. Wagner CA, Lukewille U, Kaltenbach S, et al. Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2. Am J Physiol Renal Physiol 2000; 279(3): F584-91.
272. Ohashi R, Tamai I, Yabuuchi H, et al. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 1999; 291(2): 778-84.
273. Lamhonwah A-M TI, Ackerly CA, Tilups A, Edwards VD, Wanders RJ. OCTN3 is a mammalian peroxisomal membrane carnitine transporter. Biochemical and Biophys Res communicat 2005; 338: 1966-72.
274. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Archiv: Eur J Physiol 2004; 447(5): 735-43.
275. Cabrita MA, Baldwin SA, Young JD, Cass CE. Molecular biology and regulation of nucleoside and nucleobase transporter proteins in eukaryotes and prokaryotes. Biochemistry and cell biology = Biochimie et biologie cellulaire 2002; 80(5): 623-38.
276. Plagemann PG, Aran JM. Characterization of Na(+)-dependent, active nucleoside transport in rat and mouse peritoneal macrophages, a mouse macrophage cell line and normal rat kidney cells. Biochimica Biophysica Acta 1990; 1028(3): 289-98.
277. Baldwin SA, Yao SY, Hyde RJ, et al. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biological Chem 2005; 280(16): 15880-7.
278. Sundaram M, Yao SY, Ingram JC, et al. Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. J Biological Chem 2001; 276(48): 45270-5.
279. Hyde RJ, Cass CE, Young JD, Baldwin SA. The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membrane Biol 2001; 18(1): 53-63.
280. Mani RS, Hammond JR, Marjan JM, et al. Demonstration of equilibrative nucleoside transporters (hENT1 and hENT2) in nuclear envelopes of cultured human choriocarcinoma (BeWo) cells by functional reconstitution in proteoliposomes. J Biological Chem 1998; 273(46): 30818-25.
281. Crawford CR, Patel DH, Naeve C, Belt JA. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biological Chem 1998; 273(9): 5288-93.
282. Pastor-Anglada M, Felipe A, Casado FJ. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends in pharmacol Sci 1998; 19(10): 424-30.
283. Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biological Chem 2004; 279(48): 50042-9.
284. Ritzel MW, Yao SY, Ng AM, Mackey JR, Cass CE, Young JD. Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Molecular Membrane Biol 1998; 15(4): 203-11.
285. Ritzel MW, Ng AM, Yao SY, et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biological Chem 2001; 276(4): 2914-27.
286. Wu X, Yuan G, Brett CM, Hui AC, Giacomini KM. Sodiumdependent nucleoside transport in choroid plexus from rabbit. Evidence for a single transporter for purine and pyrimidine nucleosides. J Biological Chem 1992; 267(13): 8813-8.
287. Crawford CR, Ng CY, Noel LD, Belt JA. Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters. J Biological Chem 1990; 265(17): 9732-6.
288. Smith KM, Slugoski MD, Loewen SK, et al. The broadly selective human Na+/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics. J Biological Chem 2005; 280(27): 25436-49.
289. Hamilton SR, Yao SY, Ingram JC, et al. Subcellular distribution and membrane topology of the mammalian concentrative Na+-nucleoside cotransporter rCNT1. J Biological Chem 2001; 276(30): 27981-8.
290. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx: J Am SocExperimental NeuroTherapeut 2005; 2(1): 3-14.
291. Anderson CM, Xiong W, Young JD, Cass CE, Parkinson FE. Demonstration of the existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat brain. Brain Res Mol Brain Res 1996; 42(2): 358-61.
292. Lu H, Chen C, Klaassen C. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug metabolism and disposition: Biological Fate Chemicals 2004; 32(12): 1455-61.
293. Graham KA, Leithoff J, Coe IR, et al. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1. Nucleosides, Nucleotides Nucleic Acids 2000; 19(1-2): 415-34.
294. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Communicat 2001; 280(3): 951-9.
295. Nagai K, Nagasawa K, Fujimoto S. Transport mechanisms for adenosine and uridine in primary-cultured rat cortical neurons and astrocytes. Biochem Biophys Res Communicat 2005; 334(4): 1343-50.
296. Redzic ZB, Biringer J, Barnes K, et al. Polarized distribution of nucleoside transporters in rat brain endothelial and choroid plexus epithelial cells. J Neurochem 2005; 94(5): 1420-6.
297. Ritzel MW, Ng AM, Yao SY, et al. Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Molecular Membrane Biol 2001; 18(1): 65-72.
298. Herrera-Ruiz D, Knipp GT. Current perspectives on established and putative mammalian oligopeptide transporters. J Pharm Sci 2003; 92(4): 691-714.
299. Daniel H, Kottra G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Archiv: Eur J Physiol 2004; 447(5): 610-8.
300. Carl SMH-RD, Bhardwaj RK, Gudmundsson O, Knipp GT. Mammalian Oligopeptide Transporters. In: You GMME, editor. Drug Transporters: molecular characterization and role in drug disposition. Hoboken, NJ: John Wiley & Sons, Inc.; 2007. p. 105-46.
301. Ocheltree SM, Shen H, Hu Y, Keep RF, Smith DE. Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther 2005; 315(1): 240-7.
302. Brandsch M, Brandsch C, Prasad PD, Ganapathy V, Hopfer U, Leibach FH. Identification of a renal cell line that constitutively expresses the kidney-specific high-affinity H+/peptide cotransporter. FASEB journal: official publication of the Federation Am Soc Experimental Biol 1995; 9(14): 1489-96.
303. Ganapathy V, Leibach FH. Role of pH gradient and membrane potential in dipeptide transport in intestinal and renal brush-border membrane vesicles from the rabbit. Studies with L-carnosine and glycyl-L-proline. JJ Biological Chem 1983; 258(23): 14189-92.
304. Thwaites DT, Kennedy DJ, Raldua D, et al. H/dipeptide absorption across the human intestinal epithelium is controlled indirectly via a functional Na/H exchanger. Gastroenterology 2002; 122(5): 1322-33.
305. Kennedy DJ, Leibach FH, Ganapathy V, Thwaites DT. Optimal absorptive transport of the dipeptide glycylsarcosine is dependent on functional Na+/H+ exchange activity. Pflugers Archiv: Eur J Physiol 2002; 445(1): 139-46.
306. Fujita T, Kishida T, Okada N, Ganapathy V, Leibach FH, Yamamoto A. Interaction of kyotorphin and brain peptide transporter in synaptosomes prepared from rat cerebellum: implication of high affinity type H+/peptide transporter PEPT2 mediated transport system. Neurosci letters 1999; 271(2): 117-20.
307. Shen H, Smith DE, Keep RF, Brosius FC, 3rd. Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in developing rat brain. Mol Pharm 2004; 1(4): 248-56.
308. Knutter I, Rubio-Aliaga I, Boll M, et al. H+-peptide cotransport in the human bile duct epithelium cell line SK-ChA-1. American J Physiol Gastrointestinal liver Physiol 2002; 283(1): G222-9.
309. Fujita T, Kishida T, Wada M, et al. Functional characterization of brain peptide transporter in rat cerebral cortex: identification of the high-affinity type H+/peptide transporter PEPT2. Brain Res 2004; 997(1): 52-61.
310. Boll M, Markovich D, Weber WM, Korte H, Daniel H, Murer H. Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, beta-lactam antibiotics and ACE-inhibitors. Pflugers Archiv: Eur J Physiol 1994; 429(1): 146-9.
311. Boll M, Herget M, Wagener M, et al. Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter. Proc Natl Acad Sci USA 1996; 93(1): 284-9.
312. Xiang J, Chiang PP, Hu Y, Smith DE, Keep RF. Role of PEPT2 in glycylsarcosine transport in astrocyte and glioma cultures. Neurosci letters 2006; 396(3): 225-9.
313. Berger UV, Hediger MA. Distribution of peptide transporter PEPT2 mRNA in the rat nervous system. Anatom Embryol 1999; 199(5): 439-49.
314. Daniel H, Herget M. Cellular and molecular mechanisms of renal peptide transport. Am J Physiol 1997; 273(1 Pt 2): F1-8.
315. Dringen R, Hamprecht B, Broer S. The peptide transporter PepT2 mediates the uptake of the glutathione precursor CysGly in astroglia-rich primary cultures. J Neurochem 1998; 71(1): 388-93.
316. Teuscher NS, Novotny A, Keep RF, Smith DE. Functional evidence for presence of PEPT2 in rat choroid plexus: studies with glycylsarcosine. J Pharmacol Exp Ther 2000; 294(2): 494-9.
317. Shu C, Shen H, Teuscher NS, Lorenzi PJ, Keep RF, Smith DE. Role of PEPT2 in peptide/mimetic trafficking at the bloodcerebrospinal fluid barrier: studies in rat choroid plexus epithelial cells in primary culture. J Pharmacol Exp Ther 2002; 301(3): 820-9.
318. Novotny A, Xiang J, Stummer W, Teuscher NS, Smith DE, Keep RF. Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J Neurochem 2000; 75(1): 321-8.
319. Yamashita T, Shimada S, Guo W, et al. Cloning and functional expression of a brain peptide/histidine transporter. J Biological Chem 1997; 272(15): 10205-11.
320. Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther 1999; 289(1): 448-54.
321. Banks WA, Kastin AJ, Ehrensing CA. Endogenous peptide Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1) is transported from the brain to the blood by peptide transport system-1. J Neurosci Res 1993; 35(6): 690-5.
322. Banks WA, Kastin AJ, Harrison LM, Zadina JE. Perinatal treatment of rats with opiates affects the development of the bloodbrain barrier transport system PTS-1. Neurotoxicol Teratol 1996; 18(6): 711-5.
323. Banks WA, Kastin AJ, Komaki G, Arimura A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther 1993; 267(2): 690-6.
324. Dogrukol-Ak D, Kumar VB, Ryerse JS, et al. Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models. J Cereb Blood Flow Metab 2009; 29(2): 411-22.
325. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 2000; 52(2): 269-324.
326. Spanier JAD, L. R. Monocarboxylate Transporters. In: You GMME, editor. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Hoboken, NJ: John Wiley & Sons, Inc.; 2007. p. 147-70.
327. Kim DK, Kanai Y, Matsuo H, et al. The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics 2002; 79(1): 95-103.
328. Halestrap AP. The monocarboxylate transporter family--Structure and functional characterization. IUBMB life 2012; 64(1): 1-9.
329. Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H. Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biological Chem 2001; 276(20): 17221-8.
330. Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biological Chem 2003; 278(41): 40128-35.
331. Meredith D, Christian HC. The SLC16 monocaboxylate transporter family. Xenobiotica; Fate Foreign Compounds iological Systems 2008; 38(7-8): 1072-106.
332. Gerhart DZ, Enerson BE, Zhdankina OY, Leino RL, Drewes LR. Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. Am J Physiol 1997; 273(1 Pt 1): E207-13.
333. Leino RL, Gerhart DZ, Drewes LR. Monocarboxylate transporter (MCT1) abundance in brains of suckling and adult rats: a quantitative electron microscopic immunogold study. Brain Res Developmental Brain Res 1999; 113(1-2): 47-54.
334. Broer S, Rahman B, Pellegri G, et al. Comparison of lactate transport in astroglial cells and monocarboxylate transporter 1 (MCT 1) expressing Xenopus laevis oocytes. Expression of two different monocarboxylate transporters in astroglial cells and neurons. J Biological Chem 1997; 272(48): 30096-102.
335. Pierre K, Pellerin L. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J Neurochem 2005; 94(1): 1-14.
336. Balmaceda-Aguilera C, Cortes-Campos C, Cifuentes M, et al. Glucose transporter 1 and monocarboxylate transporters 1, 2, and 4 localization within the glial cells of shark blood-brain-barriers. PloS one 2012; 7(2): e32409.
337. Koehler-Stec EM, Simpson IA, Vannucci SJ, Landschulz KT, Landschulz WH. Monocarboxylate transporter expression in mouse brain. Am J Physiol 1998; 275(3 Pt 1): E516-24.
338. Vannucci SJ, Simpson IA. Developmental switch in brain nutrient transporter expression in the rat. Am J Physiol Endocrinol Metabol 2003; 285(5): E1127-34.
339. Bergersen L, Waerhaug O, Helm J, et al. A novel postsynaptic density protein: the monocarboxylate transporter MCT2 is colocalized with delta-glutamate receptors in postsynaptic densities of parallel fiber-Purkinje cell synapses. Exp Brain Res Exp Hirnforschung Experimentation Cerebrale 2001; 136(4): 523-34.
340. Rafiki A, Boulland JL, Halestrap AP, Ottersen OP, Bergersen L. Highly differential expression of the monocarboxylate transporters MCT2 and MCT4 in the developing rat brain. Neuroscience 2003; 122(3): 677-88.
341. Enerson BE, Drewes LR. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J Pharm Sci 2003; 92(8): 1531-44.
342. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S. The lowaffinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000; 350 Pt 1: 219-27.
343. Manning Fox JE, Meredith D, Halestrap AP. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol 2000; 529 Pt 2: 285-93.
344. Tsuji A, Saheki A, Tamai I, Terasaki T. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 1993; 267(3): 1085-90.
345. Tamargo RJ, Rossell LA, Kossoff EH, Tyler BM, Ewend MG, Aryanpur JJ. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res 2002; 48(3): 145-55.
346. Barcia JA, Gallego JM. Intraventricular and intracerebral delivery of anti-epileptic drugs in the kindling model. Neurotherapeutics: J Am Soc Exp NeuroTherapeut 2009; 6(2): 337-43.
347. Pathan SA, Iqbal Z, Zaidi SM, et al. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul 2009; 3(1): 71-89.
348. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cellular Mol Neurobiol 2000; 20(2): 217-30.
349. Nagashima T, Ikeda K, Wu S, Kondo T, Yamaguchi M, Tamaki N. The mechanism of reversible osmotic opening of the blood-brain barrier: role of intracellular calcium ion in capillary endothelial cells. Acta Neurochirurgica Supplement 1997; 70: 231-3.
350. Bhattacharjee AK, Nagashima T, Kondoh T, Tamaki N. The effects of the Na(+)/Ca(++) exchange blocker on osmotic blood-brain barrier disruption. Brain Res 2001; 900(2): 157-62.
351. Haluska M, Anthony ML. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors. Clin J Oncol Nursing 2004; 8(3): 263-7.
352. Remsen LG, Pagel MA, McCormick CI, Fiamengo SA, Sexton G, Neuwelt EA. The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts. Anesthesia Analgesia 1999; 88(3): 559-67.
353. Rapoport SI. Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Exp Opinion Investigational Drugs 2001; 10(10): 1809-18.
354. Burgess A, Hynynen K. Noninvasive and Targeted Drug Delivery to the Brain Using Focused Ultrasound. ACS Chemical Neurosci 2013.
355. Bing KF, Howles GP, Qi Y, Palmeri ML, Nightingale KR. Bloodbrain barrier (BBB) disruption using a diagnostic ultrasound scanner and Definity in Mice. Ultrasound Med Biol 2009; 35(8): 1298-308.
356. Liu HL, Pan CH, Ting CY, Hsiao MJ. Opening of the blood-brain barrier by low-frequency (28-kHz) ultrasound: a novel pinholeassisted mechanical scanning device. Ultrasound Med Biol 2010; 36(2): 325-35.
357. Blomley MJ, Cooke JC, Unger EC, Monaghan MJ, Cosgrove DO. Microbubble contrast agents: a new era in ultrasound. BMJ (Clinical research ed) 2001; 322(7296): 1222-5.
358. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001; 220(3): 640-6.
359. Mesiwala AH, Farrell L, Wenzel HJ, et al. High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo. Ultrasound Med Biol 2002; 28(3): 389-400.
360. Alkins RD, Burgess A, Ganguly M, et al. Focused Ultrasound Delivers Targeted Immune Cells To Metastatic Brain Tumors. Cancer Res 2013.
361. Park EJ, Zhang YZ, Vykhodtseva N, McDannold N. Ultrasoundmediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J controlled release: official J Controlled Release Soc 2012; 163(3): 277-84.
362. Levi H, Schoknecht K, Prager O, et al. Stimulation of the sphenopalatine ganglion induces reperfusion and blood-brain barrier protection in the photothrombotic stroke model. PloS one 2012; 7(6): e39636.
363. Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci USA 2012; 109(39): 15930-5.
364. Hawkins BT, Rigor RR, Miller DS. Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. J Cereb Blood Flow Metab 2010; 30(9): 1593-7.
365. Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J. By-passing of P-glycoprotein using immunoliposomes. J drug targeting 2002; 10(1): 73-9.
366. Markoutsa E, Pampalakis G, Niarakis A, et al. Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. European J pharmaceutics and biopharmaceutics: official JJ Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 2011; 77(2): 265-74.
367. Pan W, Kastin AJ, Zankel TC, van Kerkhof P, Terasaki T, Bu G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J Cell Sci 2004; 117(Pt 21): 5071-8.
368. Demeule M, Currie JC, Bertrand Y, et al. Involvement of the lowdensity lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 2008; 106(4): 1534-44.
369. Thomas FC, Taskar K, Rudraraju V, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 2009; 26(11): 2486-94.
370. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interventions 2003; 3(2): 90-105, 51.
371. Cornford EM, Young D, Paxton JW, Finlay GJ, Wilson WR, Pardridge WM. Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res 1992; 52(1): 138-43.
372. Uchino H, Kanai Y, Kim DK, et al. Transport of amino acidrelated compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 2002; 61(4): 729-37.
373. Dagenais C, Graff CL, Pollack GM. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochemical Pharmacol 2004; 67(2): 269-76.
374. Ose A, Kusuhara H, Endo C, et al. Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug metabolism and disposition: the biological fate Chemicals 2010; 38(1): 168-76.
375. Egleton RD, Davis TP. Transport of the delta-opioid receptor agonist [D-penicillamine2, 5] enkephalin across the blood-brain barrier involves transcytosis1. J Pharm Sci 1999; 88(4): 392-7.
376. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovascular Res 2005; 65(3): 599-608.
377. Dohgu S, Yamauchi A, Takata F, et al. Transforming growth factor-beta1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cellular Mol Neurobiol 2004; 24(3): 491-7.
378. Zhang LL, Lu L, Jin S, et al. Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocininduced diabetic rats. Acta Pharmacol Sinica 2011; 32(7): 956-66.
379. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2008; 73(5): 1444-53.
380. Largent-Milnes TM, Yamamoto T, Nair P, et al. Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. JBr J Pharmacol 2010; 161(5): 986-1001.
381. Yamamoto T, Nair P, Jacobsen NE, et al. Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists. J medicinal chemistry 2009; 52(16): 5164-75.
382. Robey RWPO, Deeken J, To KKW, Bates SE. Breast Cancer Resistance Protein. In: You GMME, editor. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Hoboken, NJ: John Wiley & Sons Inc 2007; p: 319-58.